Mekk3 is essential for early embryonic cardiovascular development

Nature Genetics

Volumn 24, Issue 3, 2000, Pages 309-313

  Yang, Jianhua ^a   Boerm, Melynda ^a   McCarty, Marya ^a   Bucana, Corazon ^a   Fidler, Isaiah J ^a   Zhuang, Yuan ^b   Su, Bing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; MITOGEN ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYO; GENE CONTROL; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE INDUCTION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD VESSELS; EMBRYONIC AND FETAL DEVELOPMENT; FETAL HEART; FETAL PROTEINS; GENES, LETHAL; GENOTYPE; GESTATIONAL AGE; MAP KINASE KINASE KINASE 3; MAP KINASE KINASE KINASES; MICE; MICE, KNOCKOUT; MORPHOGENESIS; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; YOLK SAC;

ANIMALIA;

EID: 0034050739     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/73550     Document Type: Article

References (23)

1. Folkman, J. et al. Blood vessel formation: what is its molecular basis? Cell 87, 1153-1155 (1996).
2. Hanahan, D. Signaling vascular morphogenesis and maintenance. Science 277, 48-50 (1997).
3. Risau, W. Mechanisms of angiogenesis. Nature 386, 671-674 (1997).
4. Yancopoulos, G.D. et al. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93, 661-664 (1998).
5. Blank, J.L. et al. Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J. Biol. Chem. 271, 5361-5368 (1996).
6. Ellinger-Ziegelbauer, H. et al. Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein kinase/ERK kinase kinase 3 (MEKK) derivative. J. Biol. Chem. 272, 2668-2674 (1997).
7. 2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3. MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo. J. Biol. Chem. 272, 14489-14496 (1997).
8. 2-terminal kinases. J. Biol. Chem. 274, 16604-16610 (1999).
9. Fong, G.H. et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 (1995).
10. Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66 (1995).
11. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
12. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996).
13. Shalaby, F. et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89, 981-990 (1997).
14. Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180 (1996).
15. Dumont, D.J. et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8, 1897-1909 (1994).
16. Sato, T.N. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74 (1995).
17. Puri, M.C. et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14, 5884-5891 (1995).
18. Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997).
19. Han, J. et al. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386, 296-299 (1997).
20. Lin, Q. et al. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276, 1404-1407 (1997).
21. Lin, Q. et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 125, 4565-4574 (1998).
22. Bi, W. et al. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Dev. Biol. 211, 255-267 (1999).
23. Yang, J. et al. Molecular cloning and characterization of a human protein kinase that specifically activates c-Jun N-terminal kinase. Gene 212, 95-102 (1998).